 It thus seemed to us justified to compare a standard arm, the vinorelbine or the gemcitabine with the choice of the center in monotherapy with an experimental arm, association carboplatine paclitaxel. To avoid skewing the results by the introduction of a second line to the choice of the investigator, we chose to force it. It is thus the erlotinib which in a recent test presented by the NCIC at the ASCO 2004 proved its effectiveness in second or third line at the same time in term of response but more especially survival compared to the purely palliative care. 